We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-of-Its-Kind Test Determines Future Risk of Esophageal Cancer in Patients with Barrett's Esophagus

By LabMedica International staff writers
Posted on 24 Nov 2023

Barrett's esophagus, a condition characterized by the esophageal lining becoming similar to the intestinal tissue, typically arises from prolonged acid reflux or gastroesophageal reflux disease (GERD). More...

As the sole known precursor and a significant risk factor for esophageal cancer, a notably aggressive cancer with only a 20% five-year survival rate following diagnosis, Barrett's esophagus demands consistent monitoring and management. Identifying patients with Barrett's esophagus who are likely to progress to high-grade dysplasia or esophageal cancer is crucial for improving survival rates. Now, a first-of-its-kind test enables accurate prognosis and detection of patients with Barrett's esophagus who may be prone to esophageal cancer.

Previse (Baltimore, MD, USA) has launched Esopredict, an innovative laboratory-developed test that empowers gastroenterologists with the tools to customize Barrett's esophagus treatment. Esopredict offers reliable risk assessments for a five-year period by analyzing DNA methylation changes in four specific genes within a sample of the patient's Barrett's esophagus cells. The test results in an Esoscore, a detailed report that gauges the patient's risk of developing esophageal cancer in the future. The Esoscore is pivotal in aiding gastroenterologists to decide on the most suitable treatment, necessary steps, and surveillance intensity for patients with Barrett's esophagus. Esopredict allows for a more personalized treatment approach, taking into account each patient's unique health profile and needs. This advancement in medical testing marks a significant step forward in accurately predicting and managing the risks associated with Barrett's esophagus.

"After dedicating decades of my career to cancer research, I am proud to launch Esopredict™ with the Previse team," said Dr. Stephen Meltzer, Co-Founder and Chief Medical Officer of Previse. “With the specific data provided by Esopredict, GI specialists can now provide critical information to patients and health care providers, effectively managing risk of a future cancer diagnosis which could ultimately lead to lives.”

Related Links:
Previse 


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.